Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BMY 25067

Known as: BMY-25067 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryBMY-25067, N-7[2-(4-nitrophenyldithio)-ethyl] mitomycin C was selected from a number of disulfide derivatives of the… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
1995
1995
This study describes characteristics of a human bladder cancer cell line, SCaBER/R, selected for resistance to a mitomycin C (MMC… Expand
1995
1995
Mitomycin C (MC), mitomycin A, porfiromycin, BMY-25067, and BMY-25287, antitumor antibiotics collectively termed "mitosanes… Expand
1994
1994
This study was undertaken to elucidate the mechanism(s) of differential sensitivity of human bladder cancer cell lines J82 and… Expand
  • figure I
  • table I
  • table II
  • figure 2
1993
1993
The molecular cytotoxic mechanisms of mitomycin C (MMC) and its analogs, BMY 25282 and BMY 25067, have been investigated using… Expand
1992
1992
BMY 25282 and BMY 25067, analogues of mitomycin C (MMC), were synthesized in an attempt to increase the therapeutic potential of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Review
1991
Review
1991
  • C. Erlichman
  • Current opinion in oncology
  • 1991
  • Corpus ID: 13042388
The development of new chemotherapeutic agents for cancer treatment is pursued with the hope of finding compounds with novel… Expand
Review
1990
Review
1990
Programs directed towards the selection of etoposide and mitomycin C analogs which exhibit superior activity, reduced toxicity… Expand
1989
1989
The potential cardiotoxicity, nephrotoxicity, and pulmonary toxicity of several mitomycin (MMC) derivatives, BMY-25067 (N-7-[2-(4… Expand